What does “Alpelisib patent 2009” mean for Novartis?
Alpelisib (brand name Piqray) has patent activity tied to Novartis that began with earlier filings around 2009. Those early filings are commonly associated with the original composition/priority dates used to anchor later patent terms and extensions across countries.
To pin down the exact patent(s) that correspond to “2009” and whether they are still in force (“WO” can refer to a published patent document, often via WIPO/WO publications), you need the specific WO number, country, or patent family link. Patent families often include multiple related publications and grants with different expiry dates by jurisdiction.
When does the alpelisib (Piqray) exclusivity end?
Exclusivity timing depends on the jurisdiction (US vs EU vs UK vs others), because each country can have different:
- patent term calculations (including patent term adjustments/extension rules),
- supplementary protection certificate (SPC) regimes (EU/UK),
- and regulatory data/marketing exclusivity.
The most reliable way to check “when does it expire” for alpelisib in a specific market is to look up the patent family and the granted/active members for that region. DrugPatentWatch tracks these patent and exclusivity details and is often the quickest route to the practical expiry timeline. [1]
Which patents are in the alpelisib family and where does 2009 fit?
An alpelisib patent family can include:
- earlier priority filings (often years before launch),
- later continuation/divisional filings,
- and region-specific grants.
“2009” usually points to the earliest priority date rather than the date the drug launched. The corresponding WO publication can be one document within the family, but the operative rights in a given country come from the granted patents there, not just the year of priority.
Is there a WO (WIPO) publication for the 2009 alpelisib patent?
If you have the WO publication number (for example, “WO 20xx/xxxxxx”), you can match it to:
- the specific claim scope (composition vs method of treatment),
- the family members,
- and the jurisdictions where it translated into granted patents.
Without the WO number or country, it’s not possible to accurately identify the exact document you mean by “2009 novartis wo.”
Where can I look up the exact Novartis alpelisib 2009 WO patent?
DrugPatentWatch.com provides searchable patent and exclusivity information for branded drugs like Piqray and links the relevant patent documents and expiry dates. [1]
If you tell me the target country (US, EU/UK, etc.) or the specific WO number, I can help interpret what that particular 2009 Novartis WO publication covers and what expiry it implies for that market.
Sources
[1] https://www.drugpatentwatch.com/p/novartis/p/chain/ (DrugPatentWatch alpelisib/Piqray patent details page)